FDA expands scope of ovarian cancer drug

The US Food and Drug Administration has approved Roche-group Genentech’s application to market Avastin for patients with a specific type of ovarian cancer. The drug has been cleared for use, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by Avastin alone, to treat patients with platinum-sensitive recurrent

Continue Reading